Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer (Q84356593)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 14, 2011

edit

Language	Label	Description	Also known as
English	Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer	scientific article published on June 14, 2011

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

title

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

main subject

axitinib

1 reference

stated in

ChEBI release 2020-05-28

ChEBI ID

66910

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Jean-Philippe Spano

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

Sinil Kim

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

Olivier Rixe

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

Malcolm J. Moore

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21670972

retrieved

4 December 2024

Yazdi K. Pithavala

series ordinal

3

ORCID iD

0000-0003-2301-0538

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21670972

retrieved

4 December 2024

Alejandro D. Ricart

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21670972

retrieved

4 December 2024

language of work or name

English

1 reference

stated in

National Center for Biotechnology Information

PubMed publication ID

21670972

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21670972

retrieved

4 December 2024

publication date

14 June 2011

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

full work available at URL

https://link.springer.com/content/pdf/10.1007/s10637-011-9697-2.pdf

file format

Portable Document Format

1 reference

stated in

Crossref

DOI

10.1007/S10637-011-9697-2

reference URL

https://api.crossref.org/works/10.1007/S10637-011-9697-2

retrieved

4 December 2024

https://link.springer.com/article/10.1007/s10637-011-9697-2/fulltext.html

file format

HTML

1 reference

stated in

Crossref

DOI

10.1007/S10637-011-9697-2

reference URL

https://api.crossref.org/works/10.1007/S10637-011-9697-2

retrieved

4 December 2024

http://link.springer.com/content/pdf/10.1007/s10637-011-9697-2

1 reference

stated in

Crossref

DOI

10.1007/S10637-011-9697-2

reference URL

https://api.crossref.org/works/10.1007/S10637-011-9697-2

retrieved

4 December 2024

published in

Investigational New Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

volume

30

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

page(s)

1531-1539

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

cites work

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2010

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21670972

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10637-011-9697-2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

Dimensions Publication ID

1008743174

0 references

PubMed publication ID

21670972

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21670972

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 February 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84356593&oldid=2284222545"